A randomized, double-blind, placebo-controlled, crossover, phase IIa study to evaluate efficacy and safety of the beta-3-adrenergic receptor agonist solabegron in subjects with irritable bowel syndrome.

Trial Profile

A randomized, double-blind, placebo-controlled, crossover, phase IIa study to evaluate efficacy and safety of the beta-3-adrenergic receptor agonist solabegron in subjects with irritable bowel syndrome.

Completed
Phase of Trial: Phase II

Latest Information Update: 02 Jun 2011

At a glance

  • Drugs Solabegron (Primary)
  • Indications Irritable bowel syndrome
  • Focus Therapeutic Use
  • Most Recent Events

    • 25 Mar 2011 Positive top-line results reported in a AltheRx media release.
    • 22 Aug 2007 Status change from in progress to completed.
    • 13 Feb 2007 Status change
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top